TP53-mutated (p53-abnormal)
Loss of the p53 'guardian of the genome', the most commonly mutated gene in cancer. In blood cancers and several solid tumours a TP53 mutation marks the highest-risk group, resistant to chemotherapy and hard to treat.
TP53 is mutated in about half of all cancers and in almost all high-grade serous ovarian and small-cell lung cancers. Where it is variable it defines risk: TP53-mutated AML and MDS (especially multi-hit) have median survivals under a year and are excluded from many trials; del(17p)/TP53 CLL is treated with BTK inhibitors rather than chemoimmunotherapy; p53-abnormal endometrial cancer (by immunohistochemistry) is the aggressive molecular class that benefits from chemotherapy and trastuzumab if HER2-positive; TP53 and RB1 co-loss in prostate and lung adenocarcinoma predicts neuroendocrine transformation. Restoring p53 (eprenetapopt, MDM2 inhibitors for wild-type tumours) has so far disappointed.
Pages like this
not linked directly; found by shared links- InstitutionNorthwell Health Cancer Institute
Shares Endometrial cancer, Chronic lymphocytic leukaemia, Ovarian cancer.
- TermGene amplification and copy-number change
Shares Cytogenetics and karyotype, MDM2.
- PathwayThe p53 network (guardian of the genome)
Shares MDM2, Li-Fraumeni syndrome (germline TP53), TP53, Chronic lymphocytic leukaemia.
- InstitutionA.C. Camargo Cancer Center
Shares Li-Fraumeni syndrome (germline TP53), TP53.
- InstitutionHospital de Clínicas de Porto Alegre
Shares Li-Fraumeni syndrome (germline TP53), TP53.
- IdeaWhich patients' blood clones will become leukaemia after treatment?
Shares TP53, Acute myeloid leukaemia, Ovarian cancer.
- TrialXPORT-EC-042 / ENGOT-EN20 / GOG-3083
Shares TP53, Endometrial cancer.
- ProductEprenetapopt
Shares TP53, Acute myeloid leukaemia.